Holen Sie sich die Stockscreener-App
2.57
1.58%
0.04
Schlusskurs vom Vortag:
$2.53
Offen:
$2.58
24-Stunden-Volumen:
187.00K
Relative Volume:
0.38
Marktkapitalisierung:
$50.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.94M
KGV:
-0.6693
EPS:
-3.84
Netto-Cashflow:
$-22.97M
1W Leistung:
-4.10%
1M Leistung:
-1.15%
6M Leistung:
-51.60%
1J Leistung:
-76.09%
1-Tages-Spanne:
$2.52
$2.63
1-Wochen-Bereich:
$2.52
$2.8899
52-Wochen-Spanne:
$1.11
$11.69
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.57 | 52.22M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-10 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2024-10-25 | Hochstufung | Maxim Group | Hold → Buy |
| 2023-12-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
What drives Annovis Bio Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
Is Annovis Bio Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
Annovis Bio Inc. Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
What analysts say about Annovis Bio Inc. stockPowerful growth strategies - jammulinksnews.com
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference - MSN
What risks could impact Annovis Bio Inc. stock performanceCapital Growth Picks - Newser
Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study - TipRanks
Why Annovis Bio Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - newser.com
What makes Annovis Bio Inc. stock price move sharplyFree Popular Stock Recommendations - Newser
How Annovis Bio Inc. stock performs during market volatilityCapital Growth Picks - newser.com
Annovis Bio's Volatility Trap: Why Risky Bets and Biotech Headwinds Spell Caution for Investors - AInvest
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR.com
Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors? - TipRanks
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025 - citybuzz -
Annovis Bio Plunges 10.13% on Analyst Price Target Cut - AInvest
Annovis Bio (ANVS) Stock Jumps Over 16% in Market Trading | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Approves Board Elections and Auditor Appointment - TipRanks
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window - FinancialContent
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - The Manila Times
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright - Defense World
Annovis Bio (ANVS) Price Target Cut by 60% by HC Wainwright | AN - GuruFocus
Annovis Bio stock price target cut to $12 at H.C. Wainwright By Investing.com - Investing.com South Africa
Annovis Bio stock price target cut to $12 at H.C. Wainwright - Investing.com Nigeria
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):